Neuroscience

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (14-18 August)  

News round-up for 14-18 August by DDW Digital Content Editor Diana Spencer. My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted… Read More

#News

Dementia
#Alzheimer's #Dementia #Inherited tauopathies #Neurodegenerative disorders #Neuroscience #Oligomerix

Preclinical data supports new approach to Alzheimer’s disease

Preclinical data has demonstrated that the oral small molecule OLX-07010 inhibits tau aggregation in a model for inherited tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Earlier this year, the company Oligomerix announced the first-in-human dosing of OLX-07010 in a Phase Ia clinical… Read More

#Editor's Choice #News

Neuroblastoma
#Cancer research #Monoclonal antibodies #Neuroscience #Oncology #Phase II trial #Renaissance Pharma

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More

#Cancer Research #News

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

New DDW Highlights episode now available

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The most impactful drug discovery news this week is all linked with scientific research… Read More

#News

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

This week in drug discovery (17-21 July)  

News round-up for 17-21 July by DDW Digital Content Editor Diana Spencer. The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant… Read More

#News

Scientific papers
#Academic #Data management #Neuroscience #Stanford University

Stanford president quits following false data accusations

The president of Stanford University in the US has announced he will resign after the university found that scientific papers he had published contained manipulated research data. The scientific misconduct inquiry did not find neuroscientist Marc Tessier-Lavigne guilty of falsifying research personally, but said that papers… Read More

#News #Trending News

Alzheimer's disease
#Alzheimer's #Clinical trials #Eli Lilly #Neuroscience

Donanemab significantly slowed decline in early Alzheimer’s disease trial 

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.   Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease… Read More

#News #Trending News

Tau proteins
#Alzheimer's #Collaboration #Neurodegenerative disorders #Neuroscience #Tau protein

Collaborators pursue anti-tau therapy for neurodegeneration

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine will start of a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and development, RCF’s… Read More

#News

#Bristol Myers Squibb #Collaboration #Evotec #Neurodegenerative disorders #Neuroscience

Evotec and BMS enter drug discovery licence agreement

Evotec and Bristol Myers Squibb (BMS) have entered into an exclusive global licence agreement, extending their neuroscience partnership. The agreement covers selected late-stage discovery programmes that were developed and progressed within the collaboration between the two companies. Evotec and BMS originally entered their neurodegeneration… Read More

#News

Neurodegenerative disorders
#Alzheimer's #Cognition Therapeutics #Interview #Neurodegenerative disorders #Neuroscience

How pharma is targeting advances in Alzheimer’s treatments

Listen to this article on the DDW Podcast: Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer’s disease. The focus of the trial is to test Cognition Therapeutics’ experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. Read More

#Exclusive Content

Mental health
#Antidepressants #Anxiety disorder #Depression #Drug discovery #Mental health #Neuroscience #Psychiatry

World Wellbeing Week 2023: Celebrating drug discovery innovation

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. World Wellbeing Week was created to celebrate the many aspects of wellbeing, from meaningful, purposeful work to financial security, physical, mental and emotional health, social resilience and empathic corporate and civic leadership, community relations… Read More

#Exclusive Content

AI brain partnership
#ACROBiosystems #Diagnostics #Electrophysiology #In vivo #Neuroscience #Partnership

Partnership to accelerate neuroscience drug discovery  

ACROBiosystems, through ACRO Certify and under its Aneuro brand, has launched in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips.   Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialisation.  Electrophysiology is a critical part… Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Axol Bioscience #Neuroscience #Stem cells #StrataStem

A step closer to ‘clinical trial in a dish’ for Alzheimer’s  

Axol Bioscience has signed an exclusive agreement with StrataStem to access and commercialise its collection of Alzheimer’s Disease (AD) patient samples.   Harnessing its stem cell expertise, Axol will reprogramme these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a range… Read More

#News

Neurons in the brain
#Algiax Pharmaceuticals #Neurology #Neuroscience #Painkillers #Phase II trial #Trial data

Phase IIa trial expanded for promising neuropathic pain drug

The independent Data Monitoring Committee (DMC) has recommended the continuation of Algiax Pharmaceuticals’ Phase IIa study with lead candidate AP-325 in chronic neuropathic pain. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France,… Read More

#News

#ALS #LifeArc #Neuroscience #Partnership #Precision medicine #PrecisionLife

Partners to advance precision medicines for MND

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate… Read More

#News

Neurons
#AAV #Genetics / genomics #High throughput screening #Neuroscience #Sania Therapeutics #University College London

Start-up will focus on medicines for neural circuit dysfunction

Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference. The company’s approach combines adeno-associated viruses (AAV) in human neural circuits with tuneable conditionally-activated ion channels. This corrects dysfunctional neural excitation. Sania’s technology… Read More

#Business & Investment #News